Eli Lilly and Company (LLY)

NYSE: LLY · Real-Time Price · USD
780.67
+1.39 (0.18%)
At close: Jul 3, 2025, 1:00 PM
780.00
-0.67 (-0.09%)
After-hours: Jul 3, 2025, 5:00 PM EDT
0.18%
Market Cap 700.84B
Revenue (ttm) 49.00B
Net Income (ttm) 11.11B
Shares Out 897.74M
EPS (ttm) 12.29
PE Ratio 63.52
Forward PE 31.25
Dividend $6.00 (0.77%)
Ex-Dividend Date Aug 15, 2025
Volume 1,450,766
Open 780.46
Previous Close 779.28
Day's Range 773.00 - 783.55
52-Week Range 677.09 - 972.53
Beta 0.40
Analysts Strong Buy
Price Target 1,014.65 (+29.97%)
Earnings Date Aug 7, 2025

About LLY

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]

Sector Healthcare
Founded 1876
Employees 47,000
Stock Exchange NYSE
Ticker Symbol LLY
Full Company Profile

Financial Performance

In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial Statements

Analyst Summary

According to 17 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price target is $1,014.65, which is an increase of 29.97% from the latest price.

Price Target
$1,014.65
(29.97% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Lilly and Novo Are the Kings of Weight-Loss Drugs. The Companies Coming for Their Crowns.

Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with Lilly and Novo.

1 day ago - Barrons

Top 50 High-Quality Dividend Stocks For July 2025

I track 50 high-quality dividend growth stocks to identify opportune investments, updating valuation ratings daily to focus on attractive opportunities. In this turbulent year, my investable universe ...

3 days ago - Seeking Alpha

Top 15 High-Growth Dividend Stocks For July 2025

My Top 15 High-Growth Dividend Stocks outperformed SPY and VIG in June, gaining 6.15% versus SPY's 5.14% and VIG's 3.41%. The list's year-to-date return is 12.59%, beating SPY every month in 2025, tho...

Other symbols: APHBACBKDKSDPZELVGPN
3 days ago - Seeking Alpha

CVS drops Lilly's Zepbound

CNBC's Angelica Peebles reports on news regarding CVS.

Other symbols: CVS
4 days ago - CNBC Television

Eli Lilly seen as the stronger bet amid escalating competition with Novo in India

The global fight between Eli Lilly and Novo Nordisk for dominance in the red-hot weight-loss drug market is shifting to India, one of the fastest-growing pharmaceutical frontiers. As rising obesity an...

9 days ago - Invezz

Lilly to launch Mounjaro pen in India to compete with Novo's Wegovy

Eli Lilly said on Thursday India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving it more options to compete with Novo Nordisk...

Other symbols: NVO
9 days ago - Reuters

Buy Eli Lilly While The Market Hesitates And Let Time Make You Dominate

Eli Lilly is positioned for a 30-50% return in the next 12 months based on a nexus of value and growth. While others hesitate on greatness, I buy at the prices everyone else wishes they did. Risks are...

9 days ago - Seeking Alpha

Weight loss and diabetes jabs linked to potentially fatal side effect

Weight loss and diabetes jabs taken by more than a million people in the UK have been linked to a potential serious side effect, with some deaths, according to data from the UK medicines regulator.

Other symbols: NVO
9 days ago - Skynews

Healthy Returns: New weight loss drug data show Eli Lilly is gaining ground

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge announces a $300 million funding round.

10 days ago - CNBC

Eli Lilly: It Is A Bet On Human Longevity

Eli Lilly's recent stock dip creates a compelling buying opportunity, with its valuation multiples falling to 2022 levels, despite explosive growth prospects and a deep, innovative product pipeline. D...

11 days ago - Seeking Alpha

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

Jared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.

11 days ago - CNBC Television

Lilly declares third-quarter 2025 dividend

INDIANAPOLIS , June 23, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2025 of $1.50 per share on outstanding common ...

12 days ago - PRNewsWire

Eli Lilly and Company (LLY) Presents at Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference Transcript

Eli Lilly and Company (NYSE:LLY) Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference June 22, 2025 7:30 PM ET Company Participants Jeffrey...

12 days ago - Seeking Alpha

Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials

Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing Lilly plans to submit efsitora f...

13 days ago - PRNewsWire

Lilly expects orforglipron obesity results in third quarter

Eli Lilly said on Saturday its experimental pill orforglipron helped diabetics lose weight and lower their blood sugar, and the company aims to announce in the third quarter trial results for the drug...

14 days ago - Reuters

Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine

The investigational once-daily pill  lowered A1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as four weeks, in adults with type 2 diabetes  In ACHIEVE-1, orforglipron a...

14 days ago - PRNewsWire

Final Trade: LLY, SHEL, USO, WMT

The final trades of the day with the Fast Money traders.

Other symbols: WMTSHELUSO
14 days ago - CNBC Television

Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says

Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo Nordisk could generate more than $30 billion in sales by 2035, analysts at TD ...

Other symbols: NVO
14 days ago - Reuters

3 'Underdog Stocks' For The Rest Of 2025

With the S&P 500 Index meandering along at a 1.69% year-to-date return, you can't fault investors looking for some juice out of their portfolios at the mid-point of 2025.

Other symbols: CNCWEN
15 days ago - Benzinga

This AI Trader Bought Meta Stock and Dumped Eli Lilly

Traders now can have an AI stockpicker make those tough investment decisions

Other symbols: META
15 days ago - Barrons

Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand

Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on meeting demand for the drug in the world's most populous country.

15 days ago - Reuters

VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Verve...

Other symbols: VERV
16 days ago - Business Wire

Lilly to appeal after UK agency opposes reimbursement for Alzheimer's drug

Eli Lilly said on Thursday it would appeal against a UK agency's recommendation to not reimburse the cost of Alzheimer's drug Kisunla, blocking access for patients seeking treatment under the country'...

16 days ago - Reuters

Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study

Scholar Rock  SRRK revealed results on Wednesday from the Phase 2 EMBRAZE proof-of-concept trial assessing apitegromab in combination with tirzepatide to preserve lean mass during tirzepatide-induced ...

Other symbols: SRRK
17 days ago - Benzinga

Beyond Obesity: Eli Lilly's Genetic Medicine Bet On Verve Therapeutics

Eli Lilly's $1.3 billion acquisition of Verve Therapeutics represents a strategic move into cardiovascular genetic medicine. The pharmaceutical behemoth paid a substantial premium of approximately 113...

17 days ago - Forbes